Zobrazeno 1 - 10
of 197
pro vyhledávání: '"35"'
Autor:
Richard L. Shapiro, Melanie Warycha, Alfred W. Kopf, Paul J. Christos, Russell S. Berman, David Polsky, Madhu Mazumdar, Farbod Darvishian, Anna C. Pavlick, Iman Osman
Publikováno v:
Cancer. 113:3341-3348
BACKGROUND. Nodular melanoma (NM) may be biologically aggressive compared with the more common superficial spreading melanoma (SSM), with recent data suggesting underlying genetic differences between these 2 subtypes. To better define the clinical be
Publikováno v:
Cancer. 51:1918-1926
The intestinal carcinoid tumors of 26 patients were stained for the presence of serotonin, gastrin, somatostatin, motilin, secretin, glucagon, pancreatic polypeptide, ACTH, and neurotensin. Argentaffin and argyrophil stains were also performed in all
Publikováno v:
Cancer. 26(2)
Thirty-five benign fibro-osseous lesions of the mandible and maxilla in the Bantu were reviewed. Their clinical and radiographic features are very similar, and it was impossible to make a definitive diagnosis on these grounds alone. Although there wa
Autor:
Stacey Stein, Michael Cecchini, Neal A. Fischbach, Jonathan Reed Sporn, Jaykumar R. Thumar, Navid Hafez, Howard S. Hochster, Kert D. Sabbath, Wei Wei, Jill Lacy, Jeremy S. Kortmansky, Nataliya Volodymyrivna Uboha, Christina M. Gomez, Can Cui
Publikováno v:
Cancer
Background TAS-102, a novel antimetabolite, is approved for treatment of refractory metastatic colorectal cancer (CRC). This study sought to determine whether the addition of TAS-102 to oxaliplatin (TAS-OX) was safe and effective in metastatic CRC pr
Autor:
Donald A. Barkauskas, Mariana M. Cajaiba, Jeffrey S. Dome, Stacey L. Berg, Joseph G. Pressey, James I. Geller, Steve Y. Cho, Brenda J. Weigel, David Hall, Elizabeth Fox, Rachel A. Kudgus, Stephen D. Voss, Malcolm A. Smith, Joel M. Reid
Publikováno v:
Cancer
Background Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate linking an antimitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). Preclinical efficacy has been noted in Wilms tumor, rhabdomyosarcoma, and neuroblastoma. Synovial s
Autor:
Jin‐Hu Fan, Jian‐Bing Wang, Huan Yang, Sanford M. Dawsey, Philip R. Taylor, You‐Lin Qiao, Christian C. Abnet
Publikováno v:
Cancer. 128:2939-2948
The objective of this study was to update the association between multivitamin supplementation and total or cause-specific mortality in a population with a high prevalence of undernutrition in China.The Linxian Dysplasia Nutrition Intervention Trial
Autor:
A. Grandinetti, Andrea Zanoni, Claudio Cordiano, M. Pavarana, Domenico Rubello, Carlo Capirci, Anna Tomezzoli, Felice Pasini, Giovanni de Manzoni
Publikováno v:
Cancer. 119:939-945
BACKGROUND: This phase 2 study was aimed at defining the pathological response rate of a neoadjuvant schedule including weekly docetaxel and cisplatin, continuous infusion (c.i.) of 5-fluorouracil (5-FU) and concomitant radiotherapy (RT) in untreated
Autor:
Hyun Cheol Chung, Jae Kyung Roh, Sung Hoon Noh, Joong Bae Ahn, Chong Kun Im, Sun Young Rha, Sang Joon Shin, Hei Cheul Jeung, Woo Ick Yang
Publikováno v:
Cancer. 117:2050-2057
BACKGROUND: The purpose of this study was to compare 2 weekly docetaxel-based regimens as first-line treatments for advanced gastric cancer and to investigate the expression of secreted protein acidic and rich in cysteine (SPARC) and its abilities to
Autor:
Yeong-Shiau Pu, Chih-Hung Hsu, Nicholas J. Vogelzang, Chia-Chi Lin, Jun Chen, Chao-Yuan Huang, Ann-Lii Cheng
Publikováno v:
Cancer. 106:1269-1275
BACKGROUND Conventional systemic chemotherapy for metastatic urothelial carcinoma (UC) such as methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) or cisplatin, methotrexate, and vinblastine (CMV) is associated with significant dose-limitin
Autor:
Glen Mills, Brian C. Barnes, M. Felicia Fontenot, Joseph E. Brierre, James L. Cole, Siva Yadlapati, David A. Rinaldi, Nancy A. Lormand, Eric J. Buller, John M. Rainey
Publikováno v:
Cancer. 95:1274-1278
BACKGROUND Multiple trials have been performed to evaluate second-line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. METHODS Patients